首页> 外文期刊>Scientific reports. >Predegenerated Schwann cells–a novel prospect for cell therapy for glaucoma: neuroprotection, neuroregeneration and neuroplasticity
【24h】

Predegenerated Schwann cells–a novel prospect for cell therapy for glaucoma: neuroprotection, neuroregeneration and neuroplasticity

机译:预期施旺细胞 - 青光眼细胞疗法的新前景:神经保护,神经循环和神经塑性

获取原文
获取外文期刊封面目录资料

摘要

Glaucoma is an optic neuropathy that leads to irreversible blindness. Because the current therapies are not sufficient to protect against glaucoma-induced visual impairment, new treatment approaches are necessary to prevent disease progression. Cell transplantation techniques are currently considered to be among the most promising opportunities for nervous system damage treatment. The beneficial effects of undifferentiated cells have been investigated in experimental models of glaucoma, however experiments were accompanied by various barriers, which would make putative treatment difficult or even impossible to apply in a clinical setting. The novel therapy proposed in our study creates conditions to eliminate some of the identified barriers described for precursor cells transplantation and allows us to observe direct neuroprotective and pro-regenerative effects in ongoing optic neuropathy without additional modifications to the transplanted cells. We demonstrated that the proposed novel Schwann cell therapy might be promising, effective and easy to apply, and is safer than the alternative cell therapies for the treatment of glaucoma.
机译:青光眼是一种视神经病变,导致不可逆转的失明。因为目前的疗法不足以防止青光眼诱导的视觉损伤,所以新的治疗方法是预防疾病进展的必要方法。电池移植技术目前被认为是神经系统损伤治疗最有希望的机会之一。已经在青光眼的实验模型中研究了未分化细胞的有益效果,但实验伴随着各种障碍,这将使推定治疗难以在临床环境中施用甚至不可能。我们研究中提出的新疗法产生了消除前体细胞移植描述的一些识别的屏障的条件,并允许我们观察在持续的视神经病变中的直接神经保护和促果实病变,而不会对移植细胞进行额外的修饰。我们证明,拟议的新型施旺细胞疗法可能是有前途,有效且易于施加的,而且比治疗青光眼的替代细胞疗法更安全。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号